The claim
His pharmaceutical company had a legitimate drug development pipeline, active partnerships, and valuable intellectual property.
Made in: Investor presentations and fundraising materials
The proof
A federal jury convicted Shkreli of securities fraud for lying to investors about the status of his pharmaceutical company's drug development pipeline and partnerships. He was sentenced to seven years in prison.
The record
United States v. Shkreli — U.S. District Court for the Eastern District of New York · No. 1:15-cr-00289
Outcome: Convicted on three counts of securities fraud and three counts of conspiracy (August 2017); sentenced to seven years
A jury or judge found fraud or false statements proven beyond a reasonable doubt at trial.
Shkreli became infamous for raising the price of Daraprim by 5,000%, but the conviction was for defrauding investors in his hedge fund and pharmaceutical companies, not for the price gouging.